NCT05505448View on ClinicalTrials.gov

A Trial to Learn if a COVID-19 Therapeutic is Safe and Well Tolerated, and How it Works in the Body of Healthy Adult Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

September 15, 2022

Primary Completion Date

May 30, 2023

Study Completion Date

May 30, 2023

Conditions
Healthy
Interventions
DRUG

REGN14284

Single ascending intravenous (IV) or subcutaneous (SC) administration per the protocol

DRUG

Matching Placebo

Single ascending IV or SC administration per the protocol

Trial Locations (1)

B-3000

Universitair Ziekenhuis Leuven Gasthuisberg Campus, Leuven

All Listed Sponsors
lead

Regeneron Pharmaceuticals

INDUSTRY